Traders should monitor for future disclosures on contract value, government procurement filings, or additional deployment details. The lack of financial terms limits immediate impact, but this could be a foundational deal for scaling in the public sector.
Price Chart
Executive Summary
Firefly Neuroscience announced a partnership with the Department of War to deploy its FDA-cleared, AI-powered EEG/ERP technology for assessing and treating PTSD and TBI in U.S. service members. While the deal expands Firefly’s commercial footprint into the defense and government health sectors, specific financial terms and scale of deployment were not disclosed.
Key Facts
- Firefly Neuroscience (AIFF) announced a partnership with the Department of War (DoW) to support assessment and treatment of PTSD and TBI in active-duty and veteran service members.
- The partnership leverages Firefly’s FDA 510(k)-cleared, AI-powered EEG/ERP platform to provide objective neurological data for diagnosis and treatment tracking.
- Specific financial terms, contract value, duration, and deployment scale are not disclosed and remain confidential.
- The company highlights the multi-billion-dollar economic burden of PTSD and TBI in the military as a key market opportunity.
- This represents a strategic expansion into U.S. government and defense health sectors, supporting Firefly’s commercial and data-gathering initiatives.
Financial Impact
Unknown — no financial terms disclosed; potential long-term revenue upside from government contracts but no immediate quantifiable impact.
Risk Factors
- No disclosed financial value or timeline reduces near-term revenue visibility.
- Government contracts often involve long sales cycles, regulatory hurdles, and funding uncertainties.
- Forward-looking statements dominate the release; actual adoption and reimbursement remain unproven.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262902 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | Press Release | $2.01 $0.9196 | ▼ −54.25% | ▼ −52.77% | $0.9400 (−53.23%) |
Sep 17, 2026 5w ago | Press Release | $1.28 $1.10 | ▼ −14.06% | ▼ −15.52% | $0.9400 (−26.56%) |
Jul 1, 2026 16w ago | EFFECT | $1.29 $1.07 | ▲ +17.05% | ▲ +14.87% | $0.9400 (+27.13%) |
Jun 26, 2026 17w ago | 8-K | $1.23 $1.11 | ▲ +9.76% | ▲ +9.48% | $0.9400 (+23.58%) |
Jun 23, 2026 17w ago | S-3/A | $1.19 $1.13 | ▲ +5.04% | ▲ +6.97% | $0.9400 (+21.01%) |
Jun 22, 2026 18w ago | 8-K | $1.31 $1.12 | ▼ −14.50% | ▼ −15.66% | $0.9400 (−28.24%) |
May 12, 2026 23w ago | 8-K | $1.80 $1.61 | ▲ +10.56% | ▲ +9.94% | $0.9400 (+47.78%) |
Apr 22, 2026 26w ago | 8-K | $2.06 $1.68 | ▼ −18.45% | ▼ −23.08% | $0.9400 (−54.37%) |
Mar 26, 2026 30w ago | Press Release | $3.02 $2.29 | ▼ −24.17% | ▼ −34.84% | $0.9400 (−68.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers